RasGRP1 is a Ras-activating exchange factor that is positively regulated by translocation to membranes. RasGRP1 contains a diacylglycerol-binding C1 domain, and it has been assumed that this domain is entirely responsible for RasGRP1 translocation. We found that the C1 domain can contribute to plasma membrane-targeted translocation of RasGRP1 induced by ligation of the B cell antigen receptor (BCR). However, this reflects cooperativity of the C1 domain with the previously unrecognized Plasma membrane Targeter (PT) domain, which is sufficient and essential for plasma membrane targeting of RasGRP1. The adjacent suppressor of PT (SuPT) domain attenuates the plasma membranetargeting activity of the PT domain, thus preventing constitutive plasma membrane localization of RasGRP1. By binding to diacylglycerol generated by BCR-coupled phospholipase C␥2, the C1 domain counteracts the SuPT domain and enables efficient RasGRP1 translocation to the plasma membrane. In fibroblasts, the PT domain is inactive as a plasma membrane targeter, and the C1 domain specifies constitutive targeting of RasGRP1 to internal membranes where it can be activated and trigger oncogenic transformation. Selective use of the C1, PT, and SuPT domains may contribute to the differential targeting of RasGRP1 to the plasma membrane versus internal membranes, which has been observed in lymphocytes and other cell types.
INTRODUCTIONRasGRP1 is a guanine nucleotide exchange factor that couples antigen receptors to the activation of Ras GTPases (Dower et al., 2000;Ebinu et al., 2000;Priatel et al., 2002;Bivona et al., 2003;Caloca et al., 2003b;Layer et al., 2003;Norment et al., 2003;Oh-hora et al., 2003;Guilbault and Kay, 2004;Perez de Castro et al., 2004;Reynolds et al., 2004;Zugaza et al., 2004;Coughlin et al., 2005;Roose et al., 2005). Deletion of the RasGRP1 gene perturbs the immunological selection and activation of lymphocytes (Dower et al., 2000;Priatel et al., 2002Priatel et al., , 2006Layer et al., 2003) and mast cells (Liu et al., 2007), whereas aberrant expression of RasGRP1 initiates oncogenic transformation of lymphocytes (Li et al., 1999;Mikkers et al., 2002;Suzuki et al., 2002;Kim et al., 2003;Dupuy et al., 2005;Klinger et al., 2005), fibroblasts (Ebinu et al., 1998;Tognon et al., 1998) and keratinocytes (Oki-Idouchi and Lorenzo, 2007).To be active as an exchange factor, RasGRP1 must be localized to cell membranes where Ras GTPases reside. This requirement provides an opportunity for positive or negative regulation. RasGRP1 contains a C1 domain that binds the lipid second messenger diacylglycerol (DAG), or DAGmimetic phorbol esters (Ebinu et al., 1998;Lorenzo et al., 2000;Shao et al., 2001;Rong et al., 2002;Carrasco and Merida, 2004;Madani et al., 2004). Treatment of cells with DAG or phorbol esters results in the translocation of RasGRP1 to membranes (Ebinu et al., 1998;Tognon et al., 1998;Bivona et al., 2003;Rambaratsingh et al., 2003;Caloca et al., 2004;Stone et al., 2004), and it stimulates Ras activation via RasGRP1 (Ebinu et al., 1998;...